This document discusses chronic leukemias and myeloproliferative disorders including chronic myeloid leukemia (CML) and myelofibrosis. CML is distinguished from other myeloproliferative disorders by the presence of the Philadelphia chromosome and BCR-ABL fusion gene. CML is characterized by leukocytosis, thrombocytosis, and anemia. It progresses through chronic, accelerated, and blast phases defined by increasing blast counts and symptoms. The massive spleen seen in CML is indicative of the underlying myeloproliferative process.
Chronic Lypmhocytic leukemia/SLL/B-PLL/T-PLL/ATLL By SOLOMON SUasb by SOLOMON SUASB
the following presenation include
Introduction/Background
• Etiology of CLL
• Symptoms
• Test and Diagnosis
• Staging
• Prognosis
• Treatment
• B Cell diseases BPLL
• T cell diseases
T-PLL
ATLL
LGLL
Chronic Lypmhocytic leukemia/SLL/B-PLL/T-PLL/ATLL By SOLOMON SUasb by SOLOMON SUASB
the following presenation include
Introduction/Background
• Etiology of CLL
• Symptoms
• Test and Diagnosis
• Staging
• Prognosis
• Treatment
• B Cell diseases BPLL
• T cell diseases
T-PLL
ATLL
LGLL
Learning Objectives:
Introduction
Definition of CML
Philadelphia Chromosome
Normal Granulopoiesis
Pathogenesis of CML
Aetiology
Incidence
Clinical Features
Phases of CML
Lab Diagnosis of CML
Course & Prognosis
Differential Diagnosis
Brief Overview of Treatment
plastic anemia is a rare bone marrow failure disorder in which the bone marrow stops making enough blood cells (red blood cells, white blood cells, and ...
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
6. CLL / SLLCLL / SLL
• Peripheral B-Cell Neoplasms
• 4% of all NHLs
• Diagnostic requirement for CLL:
Sustained Absolute lymphocyte count
=/>5000 per mm3
7. Criteria for diagnosis of CLL
A International CLL workshop (1989) criteria
1-Sustained lymphocyte count of 5000 cells/cumm – mature lymphocytes
2-BM >30% lymphoctytes
3-B-cell phenotype
Diagnosis
Criterion 1+Criterion 2 or 3 OR
If count is <10,000 then criteria 2+3 must be present
B The NCI-WG (1996) criteria
1-Lymphocyte count >5000/cumm with <55% atypical cells. The cells should
have
B-cell Ags CD19, 20, 23
CD 5 positivity
Kappa or Lambda sIg
Low density sIg
2-BM >30% lymphcoytes
8. CLL / SLL –CLL / SLL – Clinical featuresClinical features
• Older age group >60yrs
• M:F=2:1
• Painless lymphadenopathy
• Autoimmune hemolytic anemia
• Hepatosplenomegaly
9. CLL – Blood & BMCLL – Blood & BM
• Small lymphocytes
• No nucleoli
• Smudge / basket cells
• Prolymphocytes (having Nucleoli) <2%
• Nodular / diffuse infiltrates in the BM
• CD 5, 19, 20 +
• Low level expression of sIg
• CD 10 and cyclin D1 invariably negative
• Trisomy 12
• Richter’s transformation
10. B-CELL CLLB-CELL CLL
Blood smear from an adult male with
a marked lymphocytosis. The
predominant lymphocytes have very
sparse pale cytoplasm, round to
slightly oval nuclei, and no evident
nucleoli. Three damaged cells are
present. This morphology is
characteristic of the majority of cases
of B CLL. (Wright-Giemsa stain)
11. These mature lymphocytes are increased markedly in number. They are indicative of
chronic lymphocytic leukemia, a disease most often seen in older adults. This disease
responds poorly to treatment, but it is indolent.
12. B-CELL CLL, MIXED CELL TYPEB-CELL CLL, MIXED CELL TYPE
Blood smear from a man with recently
diagnosed B CLL and a leukocyte count
of 175x109/L. There is variability in the
size of the lymphocytes. The larger cells
have abundant pale cytoplasm. Some
cells have nucleoli that are not
prominent. One cell has features of a
prolymphocyte. (Wright-Giemsa stain)
13. B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: TRISOMY 12
Karyotype of a lymphocyte from a patient with B CLL showing an extra copy of
chromosome 12. (G-banded, Wright-Giemsa stained)
14. Lymphnode / Liver / SpleenLymphnode / Liver / Spleen
Morphology:
• Lymph nodes are diffusely effaced by an
infiltrate of predominantly small
lymphocytes
• Proliferation centers: Pathognomonic for
CLL/SLL
• Nodular / diffuse infiltrates in the BM
• Infiltrates are also virtually always seen in
the splenic white and red pulp and the
hepatic portal tracts
17. These infiltrates in the liver are composed of small lymphocytes. The involvement of
tissues in cases of chronic lymphocytic leukemia (CLL) is known as small lymphocytic
lymphoma (SLL). This disease, CLL/SLL, has an indolent course.
18. CHRONIC LYMPHOCYTIC
LEUKEMIA:
RICHTER TRANSFORMATION
A marrow biopsy from a patient with a
history of B CLL with a recent onset of
weight loss and fatigue. The marrow
biopsy shows a large focus of
pleomorphic cells which reacted with
B-cell antibodies. The large cells are
partially encircled by small
lymphocytes. (Hematoxylin and eosin
stain)
19. Molecular PathogenesisMolecular Pathogenesis
• Common: del of 13q14.3, 11q, and 17p
• Trisomy 12
• Deletions on Chr 13: Implicated two
microRNAs, miR-15a and miR-16-1, as
possible tumor suppressor genes
20. Course and Prognosis
• Indolent disease, incurable
• Variable and depends on the clinical stage.
• Median survival: 4 - 6 years, but over 10 years in
individuals with minimal tumor burden
• Worse outcome seen in:
– the presence of deletions of 11q and 17p,
– a lack of somatic hypermutation, and
– the expression of ZAP-70, a protein that augments signals
produced by the Ig receptor
• Patients are generally treated with “gentle”
chemotherapy to control symptoms
33. B cell PLLB cell PLL
• 70% PLL are B cell origin
• Aggressive leukemia
• Males 4x
• May develop de novo or from CLL
• DD: CLL Vs PLL
– PLL marked splenomegaly
– PLL minimal lymphadenopathy
– Prolymphocytes #
• <10% in CLL
• >55% in PLL
• Note: cases in between 10&55% are CLL/PLL. Course is
unpredictable
34. B cell PLLB cell PLL
DD: CLL Vs PLL
– PLL marked splenomegaly
– PLL minimal lymphadenopathy
– Prolymphocytes #
• <10% in CLL
• >55% in PLL
• Note: cases in between 10&55% are CLL/PLL. Course is
unpredictable
• Strong sIg, CD20, 22, FMC-7
• CD 23-
• Trisomy12, 14q+, 6q-, p53 mutation.
35. B cell PLLB cell PLL
• Absolute lymphocytosis
• Anemia
• Thrombocytopenia
• Large granular lymphocytes
39. LGL LeukemiaLGL Leukemia
• T cell neoplasm
• Large granular lymphocytes
• >15% of lymphocytes
• NK like T cells (CD3+) or NK cells (CD3-)
• DD: Reactive lymphocytosis
• By molecular diagnostics or
• By cytogenetics
41. LGL LeukemiaLGL Leukemia
T cell type
• 80%
• >50yrs
• T-LGLL may have anemia, neutropenia,
thrombocytopenia
• Lymphadenopathy and hepatomegaly –
uncommon
• 25% of patients may have Rhe.arthritis
• Indolent course (10yr survival >80%)
• CD 2,3,5,7,8,16, 57+ & 4, 56-
42. LGL LeukemiaLGL Leukemia
NK cell type
• 20%
• ~40yrs
• Presentation is like acute leukemia
• Fever and hepatosplenomegaly
• Neutropenia is rare
• 25% of patients may have Rhe.arthritis
• Felty’s syndrome
• Aggressive (Death with in 2months)
• CD 2,7,16, 56+ & 3,4,8,57-
47. Chronic Myeloid LeukemiaChronic Myeloid Leukemia
CMLCML
Def:
CML is a myeloproliferative disorder
originating from an abnormal
pluripotent stem cell and
It’s associated consistently with
Philadelphia chromosome (Ph’) and
or BCR/ABL fusion gene.
48. Chronic Myeloid LeukemiaChronic Myeloid Leukemia
CMLCML
Chronic myeloid leukemia (CML) is
distinguished from other
myeloproliferative disorders by the
presence of a chimeric BCR-ABL
gene derived from portions of the
BCR gene on chromosome 22 and
the ABL gene on chromosome 9.
49. CML – Clinical featuresCML – Clinical features
• 15-20% of leukemias
• 5th
& 6th
decade, can occur at any age
• More common in males
• Blood and BM is primarily involved
• Most of the patients are asymptomatic
• Night sweats, wt loss, anemia
• Massive splenomegaly
• Left quadrant abdominal pain
Hypermetabolism due
to increased cell
turnover
50. Chronic Myeloid LeukemiaChronic Myeloid Leukemia
CMLCML
Remember
CML is a disease of “One MillionOne Million”
Parameter Interpretation
One million RBCs Anemia
One million WBCs Leucocytosis
One million PLTs Thrombocytosis
51. CMLCML
• White count 170k
• Predominant cells are myelocytes and segmented
neutrophils
• Blast count <2%
• Basophilia
• Eosinophilia
• PLT count usually increased (1000k)
• Mild anemia
• BM: blasts <5%, paratrabacular polys 5-10 cell thick
53. CML - APCML - AP
• Blasts 10-19% in blood / BM
• Basophilia >20%
• Thrombocytopenia not related to Tx
• Increasing spleen size despite Tx
• Cytogenetic evidence of clonal
evolution
Note: for diagnosis, one or more the above
findings should be present
54. Cytochemistry and
immunophenotyping
• CML – CP markedly <NAP (LAP) score
• CML – BP may show markers of myeloid
(CD 13, 33), monocytic (CD 15, lysozyme),
MKc (CD41, 61) or erythroid (glcophorin-A,
HGB-A)
• Lymphoblastic blast phase will express
lymphoid markers (CD10,19,34 TdT et.c.)
• In 90-95% of cases - Characteristic t(9,22)
(q34; q11) (Ph’)
55. Philadelphia chromosome Ph’Ph’
• t(9,22)(q34; q11)
• Fuses BCR gene on chr# 22 with
ABL gene on chr# 9
• Others may have variations in translocation
involving other chromosomes 3, 4 in addition to 9
& 22
• BCR (on 22), break occurs in
major BCR (fusion protein p210)
µ BCR (fusion protein p 190)
m BCR (fusion protein p 230)
• Products has Tyrosine kinase activity
• Philadelphia chromosome is #22
56.
57. Prognosis
• Age at diagnosis
• Spleen size
• # of blasts and basophils in BM
• Marrow fibrosis
Tx:
Imatinib
Allogenic BM transplantation
58. This is a markedly enlarged spleen (the ruler is 15 cm long). Such massive
splenomegaly is usually indicative of some myeloproliferative disease such as chronic
myelogenous leukemia or myelofibrosis. There are subcapsular yellow-tan infarcts.
Congestive splenomegaly (as with portal hypertension in cirrhosis of the liver)
is unlikely to increase the size of the spleen over 800 gm. A spleen >1000 gm
suggests a myeloproliferative, lymphoproliferative, or hematopoietic disorder.
59. Splenic rupture results most often from blunt abdominal trauma. Seen here are two
large capsular lacerations in a patient who was involved in a motor vehicle accident.
Note the hematoma resulting from the splenic rupture. Enlargement of the spleen from
a condition such as malaria may render the spleen prone to rupture even with minor
trauma.
60.
61. The CBC here is from a patient with CML. Note the markedly increased WBC count.
740
63. There are numerous granulocytic forms seen here, including immature myeloid cells
and bands. This condition is one of the myeloproliferative states and is known as
chronic myelogenous leukemia (CML) that is most prevalent in middle-aged adults. A
useful test to help distinguish this disease is the leukocyte alkaline phosphatase (LAP)
score, which should be low with CML and high with a leukemoid reaction.
64. Here is another view of a peripheral blood smear in a patient with CML. Often, the
numbers of basophils and eosinophils, as well as bands and more immature myeloid
cells (metamyelocytes and myelocytes) are increased. Unlike AML, there are not many
blasts with CML.
67. A characteristic finding in CMLA characteristic finding in CML
Presence of scattered macrophages with
abundant wrinkled, green-blue cytoplasm
so-called sea-blue histiocytes
68. Myeloid cells of CML are also characterized by the Philadelphia chromosome (Ph1) on karyotyping. This
is a translocation of a portion of the q arm of chromosome 22 to the q arm of chromosome 9, designated
t(9:22). This translocation brings the c-abl proto-oncogene on chromosome 9 in approximation with the
bcr (breakpoint cluster) gene on chromosome 22. The hybrid bcr-c-abl gene encodes a tyrosine kinase
that has growth promoting effects through nuclear stimulation.
69. FISH technique is diagrammed above with interphase nuclei. In the left panel, probes specific for the breakpoint regions
of chromosome 8(q22) in green and chromosome 21(q22) in red identify a translocation t(8;21) in a patient with acute
myelogenous leukemia. In the center panel, probes to chromosomes 11 (green) and 13 (red) identify a deletion of 11q23
in a patient with small lymphocytic lymphoma. In the right panel, a red fluorescent tag to the BCR gene of chromosome
22 and a green tag to the ABL gene of chromosome 9 are seen, but the yellow dot identifies the abnormal BCR-ABL
fusion gene in a case of chronic myelogenous leukemia with the "Philadelphia chromosome".
AML t(8,21) SLL del 11q CML BCR-ABL fusion
Ph’
70. CML / CLL
• CML -- Women in beach
• CLL -- Children in convent
71. Here is another view of a peripheral blood smear in a patient with CML. Often, the
numbers of basophils and eosinophils, as well as bands and more immature myeloid
cells (metamyelocytes and myelocytes) are increased. Unlike AML, there are not many
blasts with CML.
72. B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA
Blood smear from an adult male with
a marked lymphocytosis. The
predominant lymphocytes have very
sparse pale cytoplasm, round to
slightly oval nuclei, and no
evident nucleoli. Three damaged cells
are present. This morphology is
characteristic of the majority of cases
of B CLL. (Wright-Giemsa stain)
For UG level CLL and Hairy cell leuekemia are important.
Here define lymphoma and leukemia again before proceeding to CLL.
Most affected patients have sufficient lymphocytosis to fulfill the diagnostic requirement for CLL (absolute lymphocyte count &gt;4000 per mm3 .
Most affected patients have sufficient lymphocytosis to fulfill the diagnostic requirement for CLL (absolute lymphocyte count &gt;4500 per mm3 .
Note: CD5 is a T-cell marker.
B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA
Blood smear from an adult male with a marked lymphocytosis. The predominant lymphocytes have very sparse pale cytoplasm, round to slightly oval nuclei, and no
evident nucleoli. Three damaged cells are present. This morphology is characteristic of the majority of cases of B CLL. (Wright-Giemsa stain)
Brunning, RD and McKenna, RW. Tumors of the bone marrow. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington D.C.:Armed Forces Institute of
Pathology, 1993. p.257.
B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA, MIXED CELL TYPE
Blood smear from a man with recently diagnosed B CLL and a leukocyte count of 175x109/L. There is variability in the size of the lymphocytes. The larger cells have
abundant pale cytoplasm. Some cells have nucleoli that are not prominent. One cell has features of a prolymphocyte. (Wright-Giemsa stain)
Brunning, RD and McKenna, RW. Tumors of the bone marrow. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington D.C.:Armed Forces Institute of
Pathology, 1993. p.258.
B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA: TRISOMY FOR
CHROMOSOME 12
Karyotype of a lymphocyte from a patient with B CLL showing an extra copy of chromosome 12. (G-banded, Wright-Giemsa stained)
Brunning, RD and McKenna, RW. Tumors of the bone marrow. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington
D.C.:Armed Forces Institute of Pathology, 1993. p.264.
Morphology. Lymph nodes are diffusely effaced by an infiltrate of predominantly small lymphocytes 6 to 12 μm in diameter with round to slightly irregular nuclei, condensed chromatin, and scant cytoplasm ( Fig. 13-7 ). Admixed are variable numbers of larger activated lymphocytes that often gather in loose aggregates referred to as proliferation centers, which contain mitotically active cells. When present, proliferation centers are pathognomonic for CLL/SLL. The blood contains large numbers of small round lymphocytes with scant cytoplasm ( Fig. 13-8 ). Some of these cells are usually disrupted in the process of making smears, producing so-called smudge cells. The bone marrow is almost always involved by interstitial infiltrates or aggregates of tumor cells. Infiltrates are also virtually always seen in the splenic white and red pulp and the hepatic portal tracts
Images taken form WHO classifiaction of tumors of hematopoietic and lymphoid tissue. And caption is from Robbin’s path 8th Ed. FIGURE 13-7 Small lymphocytic lymphoma/chronic lymphocytic leukemia (lymph node). A, Low-power view shows diffuse efface-ment of nodal architecture. B, At high power the majority of the tumor cells are small round lymphocytes. A “prolymphocyte,” a larger cell with a centrally placed nucleolus, is also present in this field (arrow). (A, Courtesy of Dr. José Hernandez, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
FIGURE 13-9 Small lymphocytic lymphoma/chronic lymphocytic leukemia involving the liver. Low-power view of a typical periportal lymphocytic infiltrate. (Courtesy of Dr. Mark Fleming, Department of Pathology, Children&apos;s Hospital, Boston, MA.)
CHRONIC LYMPHOCYTIC LEUKEMIA:
RICHTER TRANSFORMATION
A marrow biopsy from a patient with a history of B CLL with a recent onset of weight loss and fatigue. The marrow biopsy shows a large focus of pleomorphic cells
which reacted with B-cell antibodies. The large cells are partially encircled by small lymphocytes. (Hematoxylin and eosin stain)
Brunning, RD and McKenna, RW. Tumors of the bone marrow. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington D.C.:Armed Forces Institute of
Pathology, 1993. p.268.
Variable and depends on the clinical stage.
Overall median survival is 4 to 6 years, but over 10 years in individuals with minimal tumor burdens at diagnosis
Other variables that correlate with a worse outcome include
(1) the presence of deletions of 11q and 17p,
(2) a lack of somatic hypermutation, and
(3) the expression of ZAP-70, a protein that augments signals produced by the Ig receptor.
Patients are generally treated with “gentle” chemotherapy to control symptoms.
Immunotherapy with antibodies against proteins found on the surface of CLL/SLL cells, such as CD20 and CD52, is finding increasing use
Hairy cells: They are only a few in the peripheral blood. Circumferential cytoplasmic projections - hairy processes. Nuclei are oval / reniform with relatively fine chromatin. B-cell markers CD 19, 20 are strongly positive and other CD markers include 22, 25, 103 &11c are also positive.
Hairy cells: They are only a few in the peripheral blood. Circumferential cytoplasmic projections - hairy processes. Nuclei are oval / reniform with relatively fine chromatin. B-cell markers CD 19, 20 are strongly positive and other CD markers include 22, 25, 103 &11c are also positive.
Fried egg appearance.
Large granular lymphocytes: Large cells with moderate amounts of pale blue cytoplasm and azorophilic granules. Nuclear chromatin is condensed and have single prominent nucleolus.
Large granular lymphocytes: Large cells with moderate amounts of pale blue cytoplasm and azorophilic granules. Nuclear chromatin is condensed and have single prominent nucleolus.
[LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, T-CELL TYPE]. Large granular lymphocytic (LGL) leukemia, T-cell type (LGL-T) is generally an indolent chronic lymphoproliferative disorder most commonly seen in adults with unexplained anemia and /or neutropenia. The disease always involves blood and bone marrow and also commonly involves spleen and liver. This marrow shows many small-appearing lymphocytes (5 are shown with arrows) that contain granules. At this magnification granules may not be apparent in all cells. Note that some cells have indented nuclear lobes and may appear dumbbell-shaped.
[LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, T-CELL TYPE]. A higher magnification shows a large granular lymphocyte with cytoplasmic granules. Note that the large granular lymphocyte appears “small” in a bone marrow aspirate smear in contrast to larger appearance on a blood smear.
[LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, T-CELL TYPE]. Higher magnification of the core biopsy –BM- shows numerous small irregular lymphocytes present in a small cluster. Note that LGL cells in the core biopsy are often irregular with oval to elongated nuclei but are otherwise indistinguishable from other low grade B and T-cell lymphoproliferative disorders.
Chronic myeloid leukemia (CML) is distinguished from other myeloproliferative disorders by the presence of a chimeric BCR-ABL gene derived from portions of the BCR gene on chromosome 22 and the ABL gene on chromosome 9.
Chronic myeloid leukemia (CML) is distinguished from other myeloproliferative disorders by the presence of a chimeric BCR-ABL gene derived from portions of the BCR gene on chromosome 22 and the ABL gene on chromosome 9.
The Philadelphia chromosome in CML and ALL:
==============================
Q. I have a question about the Philadelphia chromosome. The Philadelphia chromosome is present in chronic myeloid leukemia. It’s also present in some case of precursor-B acute lymphoblastic leukemia. I guess I am assuming that the translocation will result in a similar gene product, but just in a different cell line. You mentioned that the Ph+ B-ALL in adults is a bad prognosis. I am wondering if this malignancy would be treated with imatinib, like CML, due to the drug targeting the specific protein that is formed (bcr-abl). If so, would there still be a bad prognosis? Thanks!
A. Great question! You are correct: a t(9;22) translocation involving the bcr and abl genes occurs in both CML and rare cases of precursor-B ALL. In some of the cases of Ph+ ALL, the genetic mutation (and gene product) is exactly the same as it is in CML; in others the breakpoint is slightly different, and a slightly different fusion protein is produced (but it is still a mutant tyrosine kinase with presumably similar effects on the malignant cells). Most cases of Ph+ ALL occurring in children have this different fusion protein, whereas only half of the cases occurring in adults have this different fusion protein (the other half of the adult cases have exactly the same breakpoint and product as is present in CML). It doesn’t seem to have any effect on prognosis whether you have the same fusion protein as in CML or the slightly different one.
You’re also correct that the genetic mutation occurs in different cell lines in each disease: in CML it is in the myeloid cell line, whereas in Ph+ ALL it is in the lymphoid cell line. One weird thing, though, is that in CML you can often find the Ph’ in lymphoid cells too. Strange. It indicates that the translocation between 9 and 22 occurs way back in a very early precursor stem cell, one that has not yet committed itself to the myeloid or lymphoid lineage. The occasional appearance of lymphoid blast crisis in CML indicates the same thing. We don’t see a similar picture in Ph+ ALL, though (there is no phase of the disease that involves myeloid cells). So perhaps in Ph+ ALL the translocation occurs in a lymphoid stem cell.
As for the treatment, it appears that imatinib is useful in Ph+ ALL. It doesn’t appear to get the patients into a long-term remission like it does in CML, unfortunately. But it does help get the patient into at least a first remission so that they can go on to bone marrow transplant (the official way to say this is that it improves early event-free survival). So the prognosis has improved somewhat for Ph+ ALL – but the outcome is nothing like the miraculous outcome in CML. Prognosis for Ph+ ALL is still very poor, both for kids and adults – in fact, Ph+ ALL has the worst prognosis of all the types of ALL.
Gleevec is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by philadelphia chromosome. It inhibits proliferation and induces apoptosis in BCR-ABL positive cell line .
Splenectomy for CML.
A characteristic finding is the presence of scattered macrophages with abundant wrinkled, green-blue cytoplasm so-called sea-blue histiocytes.
Myeloid cells of CML are also characterized by the Philadelphia chromosome (Ph1) on karyotyping. This is a translocation of a portion of the q arm of chromosome 22 to the q arm of chromosome 9, designated t(9:22). This translocation brings the c-abl proto-oncogene on chromosome 9 in approximation with the bcr (breakpoint cluster) gene on chromosome 22. The hybrid bcr-c-abl gene encodes a tyrosine kinase that has growth promoting effects through nuclear stimulation.
The fluorescent in situ hybridization (FISH) technique is diagrammed above with interphase nuclei. A specific DNA probe with a fluorescent tag identifies a specific region of a chromosome. Different colored fluorescent tags for probes allow identification of various abnormalities. In the left panel, probes specific for the breakpoint regions of chromosome 8(q22) in green and chromosome 21(q22) in red identify a translocation t(8;21) in a patient with acute myelogenous leukemia. In the center panel, probes to chromosomes 11 (green) and 13 (red) identify a deletion of 11q23 in a patient with small lymphocytic lymphoma. In the right panel, a red fluorescent tag to the BCR gene of chromosome 22 and a green tag to the ABL gene of chromosome 9 are seen, but the yellow dot identifies the abnormal BCR-ABL fusion gene in a case of chronic myelogenous leukemia with the &quot;Philadelphia chromosome&quot;.
B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA
Blood smear from an adult male with a marked lymphocytosis. The predominant lymphocytes have very sparse pale cytoplasm, round to slightly oval nuclei, and no
evident nucleoli. Three damaged cells are present. This morphology is characteristic of the majority of cases of B CLL. (Wright-Giemsa stain)
Brunning, RD and McKenna, RW. Tumors of the bone marrow. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington D.C.:Armed Forces Institute of
Pathology, 1993. p.257.
Q. I have a question about the Philadelphia chromosome. The Philadelphia chromosome is present in chronic myeloid leukemia. It’s also present in some case of precursor-B acute lymphoblastic leukemia. I guess I am assuming that the translocation will result in a similar gene product, but just in a different cell line. You mentioned that the Ph+ B-ALL in adults is a bad prognosis. I am wondering if this malignancy would be treated with imatinib, like CML, due to the drug targeting the specific protein that is formed (bcr-abl). If so, would there still be a bad prognosis? Thanks!
A. Great question! You are correct: a t(9;22) translocation involving the bcr and abl genes occurs in both CML and rare cases of precursor-B ALL. In some of the cases of Ph+ ALL, the genetic mutation (and gene product) is exactly the same as it is in CML; in others the breakpoint is slightly different, and a slightly different fusion protein is produced (but it is still a mutant tyrosine kinase with presumably similar effects on the malignant cells). Most cases of Ph+ ALL occurring in children have this different fusion protein, whereas only half of the cases occurring in adults have this different fusion protein (the other half of the adult cases have exactly the same breakpoint and product as is present in CML). It doesn’t seem to have any effect on prognosis whether you have the same fusion protein as in CML or the slightly different one.
You’re also correct that the genetic mutation occurs in different cell lines in each disease: in CML it is in the myeloid cell line, whereas in Ph+ ALL it is in the lymphoid cell line. One weird thing, though, is that in CML you can often find the Ph’ in lymphoid cells too. Strange. It indicates that the translocation between 9 and 22 occurs way back in a very early precursor stem cell, one that has not yet committed itself to the myeloid or lymphoid lineage. The occasional appearance of lymphoid blast crisis in CML indicates the same thing. We don’t see a similar picture in Ph+ ALL, though (there is no phase of the disease that involves myeloid cells). So perhaps in Ph+ ALL the translocation occurs in a lymphoid stem cell.
As for the treatment, it appears that imatinib is useful in Ph+ ALL. It doesn’t appear to get the patients into a long-term remission like it does in CML, unfortunately. But it does help get the patient into at least a first remission so that they can go on to bone marrow transplant (the official way to say this is that it improves early event-free survival). So the prognosis has improved somewhat for Ph+ ALL – but the outcome is nothing like the miraculous outcome in CML. Prognosis for Ph+ ALL is still very poor, both for kids and adults – in fact, Ph+ ALL has the worst prognosis of all the types of ALL.